{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:24:00Z","timestamp":1784816640874,"version":"3.55.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-40066-9","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:35:04Z","timestamp":1770906904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The antitumor mechanism of oclacitinib in canine lymphoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Miruki","family":"Harada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakuya","family":"Inanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusaku","family":"Shibutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehito","family":"Sugasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Osumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadatoshi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Igase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"40066_CR1","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/j.1939-1676.2008.0133.x","volume":"22","author":"DF Merlo","year":"2008","unstructured":"Merlo, D. F. et al. Cancer incidence in pet dogs: findings of the animal tumor registry of Genoa, Italy. J. Vet. Intern. Med. 22, 976\u2013984 (2008).","journal-title":"J. Vet. Intern. Med."},{"key":"40066_CR2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/01652176.2016.1152633","volume":"36","author":"M Zandvliet","year":"2016","unstructured":"Zandvliet, M. Canine lymphoma: a review. Vet. Q. 36, 76\u2013104 (2016).","journal-title":"Vet. Q."},{"key":"40066_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1476-5829.2008.00176.x","volume":"7","author":"J Fontaine","year":"2009","unstructured":"Fontaine, J., Bovens, C., Bettenay, S. & Mueller, R. S. Canine cutaneous epitheliotropic T-cell lymphoma: a review. Vet. Comp. Oncol. 7, 1\u201314 (2009).","journal-title":"Vet. Comp. Oncol."},{"key":"40066_CR4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/vde.12504","volume":"29","author":"CM Chan","year":"2018","unstructured":"Chan, C. M., Frimberger, A. E. & Moore, A. S. Clinical outcome and prognosis of dogs with histopathological features consistent with epitheliotropic lymphoma: a retrospective study of 148 cases (2003\u20132015). Vet. Dermatol. 29, 154\u2013e59 (2018).","journal-title":"Vet. Dermatol."},{"key":"40066_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0161-5890(00)00018-3","volume":"37","author":"K Imada","year":"2000","unstructured":"Imada, K. & Leonard, W. J. The Jak-STAT pathway. Mol. Immunol. 37, 1\u201311 (2000).","journal-title":"Mol. Immunol."},{"key":"40066_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3389\/fonc.2018.00287","volume":"8","author":"E Bousoik","year":"2018","unstructured":"Bousoik, E. & Montazeri Aliabadi, H. Do we know Jack about JAK? A closer look at JAK\/STAT signaling pathway. Front. Oncol. 8, 287 (2018).","journal-title":"Front. Oncol."},{"key":"40066_CR7","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu, X., Li, J., Fu, M., Zhao, X. & Wang, W. The JAK\/STAT signaling pathway: from bench to clinic. Signal. Transduct. Target. Ther. 6, 402 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"40066_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O\u2019Shea","year":"2015","unstructured":"O\u2019Shea, J. J. et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu. Rev. Med. 66, 311\u2013328 (2015).","journal-title":"Annu. Rev. Med."},{"key":"40066_CR9","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/onc.2012.347","volume":"32","author":"W Vainchenker","year":"2012","unstructured":"Vainchenker, W. & Constantinescu, S. N. JAK\/STAT signaling in hematological malignancies. Oncogene 32, 2601\u20132613 (2012).","journal-title":"Oncogene"},{"key":"40066_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrclinonc.2010.189","volume":"8","author":"A Younes","year":"2010","unstructured":"Younes, A. Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat. Rev. Clin. Oncol. 8, 85\u201396 (2010).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"40066_CR11","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1038\/sj.onc.1209151","volume":"25","author":"MA Weniger","year":"2006","unstructured":"Weniger, M. A. et al. Mutations of the tumor suppressor gene SOCS-1 in classical hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 25, 2679\u20132684 (2006).","journal-title":"Oncogene"},{"key":"40066_CR12","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.21485","volume":"118","author":"I Melzner","year":"2006","unstructured":"Melzner, I. et al. Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. Int. J. Cancer. 118, 1941\u20131944 (2006).","journal-title":"Int. J. Cancer"},{"key":"40066_CR13","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1038\/sj.onc.1209480","volume":"25","author":"V Joliot","year":"2006","unstructured":"Joliot, V., Cormier, F., Medyouf, H., Alcalde, H. & Ghysdael, J. Constitutive STAT5 activation specifically cooperates with the loss of p53 function in B-cell lymphomagenesis. Oncogene 25, 4573\u20134584 (2006).","journal-title":"Oncogene"},{"key":"40066_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1476-4598-8-67","volume":"8","author":"ZS Nagy","year":"2009","unstructured":"Nagy, Z. S. et al. STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells. Mol. Cancer. 8, 67 (2009).","journal-title":"Mol. Cancer"},{"key":"40066_CR15","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1182\/blood-2007-08-105643","volume":"111","author":"FA Scheeren","year":"2008","unstructured":"Scheeren, F. A. et al. IL-21 is expressed in hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for hodgkin lymphomagenesis. Blood 111, 4706\u20134715 (2008).","journal-title":"Blood"},{"key":"40066_CR16","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1182\/blood.V98.3.762","volume":"98","author":"D Kube","year":"2001","unstructured":"Kube, D. et al. STAT3 is constitutively activated in hodgkin cell lines. Blood 98, 762\u2013770 (2001).","journal-title":"Blood"},{"key":"40066_CR17","first-page":"316","volume":"9","author":"S Alas","year":"2003","unstructured":"Alas, S. & Bonavida, B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin\u2019s lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin. Cancer Res. 9, 316\u2013326 (2003).","journal-title":"Clin. Cancer Res."},{"key":"40066_CR18","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1182\/blood-2007-04-087734","volume":"111","author":"BB Ding","year":"2008","unstructured":"Ding, B. B. et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111, 1515\u20131523 (2008).","journal-title":"Blood"},{"key":"40066_CR19","doi-asserted-by":"publisher","first-page":"990","DOI":"10.5858\/2005-129-990-ASOTSP","volume":"129","author":"MA Yared","year":"2005","unstructured":"Yared, M. A., Khoury, J., Medeiros, L. J., Rassidakis, G. Z. & Lai, R. Activation status of the JAK\/STAT3 pathway in mantle cell lymphoma. Arch. Pathol. Lab. Med. 129, 990\u2013996 (2005).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"40066_CR20","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/sj.leu.2403750","volume":"19","author":"U Holtick","year":"2005","unstructured":"Holtick, U. et al. STAT3 is essential for hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia 19, 936\u2013944 (2005).","journal-title":"Leukemia"},{"key":"40066_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/jvp.12101","volume":"37","author":"AJ Gonzales","year":"2014","unstructured":"Gonzales, A. J. et al. Oclacitinib (APOQUEL(\u00ae)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J. Vet. Pharmacol. Ther. 37, 317\u2013324 (2014).","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"40066_CR22","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/vde.12976","volume":"32","author":"J Aslan","year":"2021","unstructured":"Aslan, J., Shipstone, M. A. & Sullivan, L. M. Treatment of canine cutaneous epitheliotropic T-cell lymphoma with oclacitinib: a case report. Vet. Dermatol. 32, 398\u2013e113 (2021).","journal-title":"Vet. Dermatol."},{"key":"40066_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.56808\/2985-1130.1122","volume":"53","author":"T Imai","year":"2024","unstructured":"Imai, T., Taguchi, N. & Hsiao, Y. H. Clinical response to oclacitinib in canine cutaneous epitheliotropic T-cell lymphoma: A case reports. Thai J. Veterinary Med. 53, 329\u2013334 (2024).","journal-title":"Thai J. Veterinary Med."},{"key":"40066_CR24","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1111\/jvim.14837","volume":"31","author":"Z Lu","year":"2017","unstructured":"Lu, Z. et al. JAK1\/2 inhibitors AZD1480 and CYT387 inhibit canine B-Cell lymphoma growth by increasing apoptosis and disrupting cell proliferation. J. Vet. Intern. Med. 31, 1804\u20131815 (2017).","journal-title":"J. Vet. Intern. Med."},{"key":"40066_CR25","first-page":"19","volume":"24","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. & Liu, Z. STAT1 in cancer: friend or foe? Discov Med. 24, 19\u201329 (2017).","journal-title":"Discov Med."},{"key":"40066_CR26","doi-asserted-by":"publisher","first-page":"1265818","DOI":"10.3389\/fimmu.2023.1265818","volume":"14","author":"W Wang","year":"2023","unstructured":"Wang, W. et al. The complementary roles of STAT3 and STAT1 in cancer biology: insights into tumor pathogenesis and therapeutic strategies. Front. Immunol. 14, 1265818 (2023).","journal-title":"Front. Immunol."},{"key":"40066_CR27","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1158\/1541-7786.MCR-16-0312","volume":"15","author":"VR Zellmer","year":"2017","unstructured":"Zellmer, V. R. et al. Tumor-induced stromal STAT1 accelerates breast cancer via deregulating tissue homeostasis. Mol. Cancer Res. 15, 585\u2013597 (2017).","journal-title":"Mol. Cancer Res."},{"key":"40066_CR28","first-page":"1987","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon, S., Keam, S. J. & Filgotinib First Approval Drugs 80, 1987\u20131997 (2020).","journal-title":"First Approval Drugs"},{"key":"40066_CR29","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.31557\/APJCP.2021.22.12.3959","volume":"22","author":"FA Al-Rawashde","year":"2021","unstructured":"Al-Rawashde, F. A. et al. Thymoquinone induces downregulation of BCR-ABL\/JAK\/STAT pathway and apoptosis in K562 leukemia cells. Asian Pac. J. Cancer Prev. 22, 3959\u20133965 (2021).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"40066_CR30","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1517\/14728222.11.10.1355","volume":"11","author":"T Meyer","year":"2007","unstructured":"Meyer, T. & Vinkemeier, U. STAT nuclear translocation: potential for Pharmacological intervention. Expert Opin. Ther. Targets. 11, 1355\u20131365 (2007).","journal-title":"Expert Opin. Ther. Targets"},{"key":"40066_CR31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/jvp.12087","volume":"37","author":"WT Collard","year":"2013","unstructured":"Collard, W. T. et al. The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog. J. Vet. Pharmacol. Ther. 37, 279\u2013285 (2013).","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"40066_CR32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/vde.12194","volume":"26","author":"SB Cosgrove","year":"2015","unstructured":"Cosgrove, S. B. et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet. Dermatol. 26, 171\u2013179 (2015). e35.","journal-title":"Vet. Dermatol."},{"key":"40066_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/vde.13053","volume":"33","author":"D Denti","year":"2022","unstructured":"Denti, D., Caldin, M., Ventura, L. & De Lucia, M. Prolonged twice-daily administration of oclacitinib for the control of canine atopic dermatitis: a retrospective study of 53 client-owned atopic dogs. Vet. Dermatol. 33, 149\u2013e42 (2022).","journal-title":"Vet. Dermatol."},{"key":"40066_CR34","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.rvsc.2018.10.014","volume":"121","author":"A Jasiecka-Miko\u0142ajczyk","year":"2018","unstructured":"Jasiecka-Miko\u0142ajczyk, A., Jaroszewski, J. J. & Ma\u015blanka, T. Oclacitinib depletes canine CD4\u2009+\u2009and CD8\u2009+\u2009T cells in vitro. Res. Vet. Sci. 121, 124\u2013129 (2018).","journal-title":"Res. Vet. Sci."},{"key":"40066_CR35","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0968-0004(97)01025-6","volume":"22","author":"C Grandori","year":"1997","unstructured":"Grandori, C. & Eisenman, R. N. Myc target genes. Trends Biochem. Sci. 22, 177\u2013181 (1997).","journal-title":"Trends Biochem. Sci."},{"key":"40066_CR36","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1146\/annurev.cellbio.16.1.653","volume":"16","author":"C Grandori","year":"2000","unstructured":"Grandori, C., Cowley, S. M., James, L. P. & Eisenman, R. N. The Myc\/Max\/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell. Dev. Biol. 16, 653\u2013699 (2000).","journal-title":"Annu. Rev. Cell. Dev. Biol."},{"key":"40066_CR37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3390\/ph15030307","volume":"15","author":"B Almajali","year":"2022","unstructured":"Almajali, B. et al. Gene expression profiling and protein analysis reveal suppression of the C-Myc oncogene and Inhibition JAK\/STAT and PI3K\/AKT\/mTOR signaling by thymoquinone in acute myeloid leukemia cells. Pharmaceuticals (Basel). 15, 307 (2022).","journal-title":"Pharmaceuticals (Basel)"},{"key":"40066_CR38","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1007\/s10120-022-01319-4","volume":"25","author":"J Zhou","year":"2022","unstructured":"Zhou, J. et al. ADAMTS10 inhibits aggressiveness via JAK\/STAT\/c-MYC pathway and reprograms macrophage to create an anti-malignant microenvironment in gastric cancer. Gastric Cancer. 25, 1002\u20131016 (2022).","journal-title":"Gastric Cancer"},{"key":"40066_CR39","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/jcb.22069","volume":"106","author":"WH Lee","year":"2009","unstructured":"Lee, W. H. et al. JAK pathway induction of c-Myc critical to IL-5 stimulation of cell proliferation and Inhibition of apoptosis. J. Cell. Biochem. 106, 929\u2013936 (2009).","journal-title":"J. Cell. Biochem."},{"key":"40066_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40164-023-00383-5","volume":"12","author":"S Gu","year":"2023","unstructured":"Gu, S. et al. Synergistic effect of HDAC inhibitor Chidamide with cladribine on cell cycle arrest and apoptosis by targeting HDAC2\/c-Myc\/RCC1 axis in acute myeloid leukemia. Exp. Hematol. Oncol. 12, 23 (2023).","journal-title":"Exp. Hematol. Oncol."},{"key":"40066_CR41","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1038\/sj.onc.1201067","volume":"14","author":"M Tsuneoka","year":"1997","unstructured":"Tsuneoka, M., Nakano, F., Ohgusu, H. & Mekada, E. c-myc activates RCC1 gene expression through E-box elements. Oncogene 14, 2301\u20132311 (1997).","journal-title":"Oncogene"},{"key":"40066_CR42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/1521-1878(200101)23:1<77::AID-BIES1010>3.0.CO;2-E","volume":"23","author":"JD Moore","year":"2001","unstructured":"Moore, J. D. The Ran-GTPase and cell-cycle control. Bioessays 23, 77\u201385 (2001).","journal-title":"Bioessays"},{"key":"40066_CR43","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1083\/jcb.151.5.951","volume":"151","author":"L Faleiro","year":"2000","unstructured":"Faleiro, L. & Lazebnik, Y. Caspases disrupt the nuclear-cytoplasmic barrier. J. Cell. Biol. 151, 951\u2013959 (2000).","journal-title":"J. Cell. Biol."},{"key":"40066_CR44","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/nri1885","volume":"6","author":"NC Reich","year":"2006","unstructured":"Reich, N. C. & Liu, L. Tracking STAT nuclear traffic. Nat. Rev. Immunol. 6, 602\u2013612 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"40066_CR45","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1182\/blood-2006-01-029918","volume":"109","author":"N Harir","year":"2006","unstructured":"Harir, N. et al. Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood 109, 1678\u20131686 (2006).","journal-title":"Blood"},{"key":"40066_CR46","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/labinvest.2009.11","volume":"89","author":"H Xiong","year":"2009","unstructured":"Xiong, H. et al. Inhibition of STAT5 induces G1 cell cycle arrest and reduces tumor cell invasion in human colorectal cancer cells. Lab. Invest. 89, 717\u2013725 (2009).","journal-title":"Lab. Invest."},{"key":"40066_CR47","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jdermsci.2017.06.001","volume":"88","author":"K Hara","year":"2017","unstructured":"Hara, K. et al. Characterization of a novel canine T-cell line established from a dog with cutaneous T-cell lymphoma. J. Dermatol. Sci. 88, 254\u2013256 (2017).","journal-title":"J. Dermatol. Sci."},{"key":"40066_CR48","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/BF00205629","volume":"24","author":"Z Steplewski","year":"1987","unstructured":"Steplewski, Z., Jeglum, K. A., Rosales, C. & Weintraub, N. Canine lymphoma-associated antigens defined by murine monoclonal antibodies. Cancer Immunol. Immunother. 24, 197\u2013201 (1987).","journal-title":"Cancer Immunol. Immunother"},{"key":"40066_CR49","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.leukres.2010.01.021","volume":"34","author":"BC R\u00fctgen","year":"2010","unstructured":"R\u00fctgen, B. C. et al. Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. Leuk. Res. 34, 932\u2013938 (2010).","journal-title":"Leuk. Res."},{"key":"40066_CR50","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1292\/jvms.12-0448","volume":"75","author":"S Umeki","year":"2013","unstructured":"Umeki, S. et al. Establishment of five canine lymphoma cell lines and tumor formation in a xenotransplantation model. J. Vet. Med. Sci. 75, 467\u2013474 (2013).","journal-title":"J. Vet. Med. Sci."},{"key":"40066_CR51","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12917-016-0836-z","volume":"12","author":"SC Roode","year":"2016","unstructured":"Roode, S. C. et al. Comprehensive genomic characterization of five canine lymphoid tumor cell lines. BMC Vet. Res. 12, 207 (2016).","journal-title":"BMC Vet. Res."},{"key":"40066_CR52","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.rvsc.2020.08.007","volume":"132","author":"Y Hamamura","year":"2020","unstructured":"Hamamura, Y. et al. The inhibitory effect of canine interferon gamma on the growth of canine tumors. Res. Vet. Sci. 132, 466\u2013473 (2020).","journal-title":"Res. Vet. Sci."},{"key":"40066_CR53","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.tvjl.2012.01.033","volume":"193","author":"SP Teng","year":"2012","unstructured":"Teng, S. P., Hsu, W. L., Chiu, C. Y., Wong, M. L. & Chang, S. C. Overexpression of P-glycoprotein, STAT3, phospho-STAT3 and KIT in spontaneous canine cutaneous mast cell tumours before and after prednisolone treatment. Vet. J. 193, 551\u2013556 (2012).","journal-title":"Vet. J."},{"key":"40066_CR54","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1158\/1940-6207.CAPR-15-0339","volume":"9","author":"K Jin","year":"2016","unstructured":"Jin, K. et al. Hepatic premalignant alterations triggered by human nephrotoxin aristolochic acid I in canines. Cancer Prev. Res. (Phila). 9, 324\u2013334 (2016).","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"40066_CR55","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/vco.12468","volume":"17","author":"M Igase","year":"2019","unstructured":"Igase, M. et al. Anti-tumour activity of oncolytic reovirus against canine Histiocytic sarcoma cells. Vet. Comp. Oncol. 17, 184\u2013193 (2019).","journal-title":"Vet. Comp. Oncol."},{"key":"40066_CR56","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1292\/jvms.24-0125","volume":"86","author":"K Ishikawa","year":"2024","unstructured":"Ishikawa, K., Chambers, J. K. & Uchida, K. Activation of the Wnt\/\u03b2-catenin signaling pathway and CTNNB1 mutations in canine intestinal epithelial proliferative lesions. J. Vet. Med. Sci. 86, 748\u2013755 (2024).","journal-title":"J. Vet. Med. Sci."},{"key":"40066_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/vde.13366","author":"Y Baba","year":"2025","unstructured":"Baba, Y. et al. Short-term administration of oclacitinib with concomitant medications in canine epitheliotropic lymphoma: A retrospective study of eight dogs. Vet. Dermatol. https:\/\/doi.org\/10.1111\/vde.13366 (2025).","journal-title":"Vet. Dermatol."},{"key":"40066_CR58","doi-asserted-by":"crossref","unstructured":"Richter, W. F., Shah, R. N. & Ruthenburg, A. J. Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia. Elife 10, e64960, (2021).","DOI":"10.7554\/eLife.64960"},{"key":"40066_CR59","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for illumina sequence data. Bioinformatics 30, 2114\u20132120 (2014).","journal-title":"Bioinformatics"},{"key":"40066_CR60","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods. 14, 417\u2013419 (2017).","journal-title":"Nat. Methods"},{"key":"40066_CR61","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated Estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40066-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40066-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40066-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:01:50Z","timestamp":1773054110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40066-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["40066"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-40066-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8427"}}